Volume 11, Number 8—August 2005

Dispatch

Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*† , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†

Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Figure A1

Figure A1. . Formulas used to analyze the impact of each strategy on health-related outcomes.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.